Imatinib (Gleevec®)-induced hepatotoxicity

Walid S. Ayoub; Stephen A. Geller; Tram Tran; Paul Martin; John M. Vierling; F. Fred Poordad

Imatinib (Gleevec®)-induced hepatotoxicity

Walid S. Ayoub, Stephen A. Geller, Tram Tran, Paul Martin, John M. Vierling, F. Fred Poordad

Producción científica: Article › revisión exhaustiva

Resumen

Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

Idioma original	English (US)
Páginas (desde-hasta)	75-77
Número de páginas	3
Publicación	Journal of Clinical Gastroenterology
Volumen	39
N.º	1
Estado	Published - ene 2005
Publicado de forma externa	Sí

ASJC Scopus subject areas

Gastroenterology

Otros archivos y enlaces

Citar esto

@article{87ce02a2b1294c74aa39dedb5cd5499a,

title = "Imatinib (Gleevec{\textregistered})-induced hepatotoxicity",

abstract = "Imatinib (Gleevec{\textregistered}, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.",

keywords = "Gleevec{\textregistered}, Hepatotoxicity, Imatinib",

author = "Ayoub, {Walid S.} and Geller, {Stephen A.} and Tram Tran and Paul Martin and Vierling, {John M.} and Poordad, {F. Fred}",

year = "2005",

month = jan,

language = "English (US)",

volume = "39",

pages = "75--77",

journal = "Journal of Clinical Gastroenterology",

issn = "0192-0790",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Imatinib (Gleevec®)-induced hepatotoxicity

AU - Ayoub, Walid S.

AU - Geller, Stephen A.

AU - Tran, Tram

AU - Martin, Paul

AU - Vierling, John M.

AU - Poordad, F. Fred

PY - 2005/1

Y1 - 2005/1

N2 - Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

AB - Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

KW - Gleevec®

KW - Hepatotoxicity

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=11144269754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144269754&partnerID=8YFLogxK

M3 - Article

C2 - 15599217

AN - SCOPUS:11144269754

SN - 0192-0790

VL - 39

SP - 75

EP - 77

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

IS - 1

ER -

Imatinib (Gleevec®)-induced hepatotoxicity

Resumen

ASJC Scopus subject areas

Otros archivos y enlaces

Huella

Citar esto